Beximco Pharmaceuticals Plc
52.50
GBX
0.00
(0.00%)
ISIN
US0885792061
CUSIP
088579206
Return %
Stock
S&P 500
1Y
25.00
14.20
3Y
40.00
81.12
5Y
-45.03
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Iqbal Ahmed
- Full Time Employees
- 1,223
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 19 Dhanmondi R/A Dhaka DA Bangladesh 1205
- IPO Date
- Oct 21, 2005
- Website
- beximcopharma.com
- Similar Companies
- Business
- Beximco Pharmaceuticals Limited (BXP.L) manufactures and markets a broad portfolio of generic pharmaceuticals, active pharmaceutical ingredients, and intravenous fluids. The company offers finished dosage forms including tablets, capsules, injections, and oral liquids across therapeutic categories such as antiulcerants, antibiotics, analgesics, antihypertensives, antidiabetics, and oncology drugs; it also produces APIs for export and provides contract manufacturing services. Beximco operates primarily in Bangladesh with exports to over 50 countries across Asia, Africa, Latin America, the Middle East, and Europe, targeting generic drug markets for emerging economies. Founded in 1972 and headquartered in Dhaka, Bangladesh, the company functions as a flagship of the Beximco Group with no major parent entity. In recent developments within the last two years, Beximco has expanded its intravenous fluid production capacity through new plant commissioning and formed strategic export partnerships in regulated markets like the US and EU; it also secured funding for R&D in biosimilars and launched several new generic formulations amid ongoing business diversification into vaccines.